Agios scores its sec­ond pos­i­tive round of da­ta for its lead pipeline drug — but that won't an­swer the stub­born ques­tions that sur­round this pro­gram

Agios $AGIO bet the farm on its PKR ac­ti­va­tor drug mi­tapi­vat when it re­cent­ly de­cid­ed to sell off its pi­o­neer­ing can­cer drug Tib­so­vo and go back to be­ing a de­vel­op­ment-stage com­pa­ny — for what CEO Jack­ie Fouse hoped would be a short stretch be­fore they got back in­to com­mer­cial­iza­tion.

On Tues­day evening, the bell­wether biotech flashed more pos­i­tive topline da­ta — this time from a small group of pa­tients in a sin­gle-arm study. And the ex­ec­u­tive team plans to pack­age this with its ear­li­er pos­i­tive re­sults from a con­trolled study to make its case for a quick OK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER